Sexual Health · 10mg × 10 vials
In plain terms: PT-141 is a research compound - injectable, fast-acting and well studied.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist, a close structural cousin of Melanotan II with the tanning effects mostly stripped out. It's a non-selective agonist at the MC1, MC3, MC4, and MC5 receptors, but the sexual-response effect is driven almost entirely by MC4R activation in the central nervous system (specifically the medial preoptic area of the hypothalamus and the paraventricular nucleus). This is a fundamentally different mechanism from Viagra/Cialis: PDE5 inhibitors work peripherally on blood flow, PT-141 works centrally on desire and arousal signaling. It increases dopaminergic tone in pro-erectile pathways in men and amplifies central sexual response in women without requiring direct genital stimulation to start the cascade. Because the trigger is upstream of vascular plumbing, PT-141 works in cases where Viagra/Cialis fail (psychogenic ED, low-desire states, SSRI-induced sexual dysfunction). The FDA approved it as Vyleesi (1.75 mg autoinjector) in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, which is the only FDA-approved on-label use, but real-world use is heavily male and unisex.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
The Vyleesi label dose is 1.75 mg; community consensus is start lower and titrate up. At 5 mg/ml reconstitution, 0.5 mg = 10 IU on a U-100 syringe, 1 mg = 20 IU. Inject 45-60 minutes before activity. Nausea is the #1 dropout reason, hits ~40% of users on the first dose, almost always settles by the 2nd or 3rd dose. Anti-nausea OTC (Dramamine, ginger) taken 30 min before the shot is the community workaround.
This is the "Vyleesi-equivalent" band and where most steady users land. Effect window opens around 30-45 minutes post-injection, peaks at 60-90 min, and runs 6-8 hours of central effect window. Pairs naturally with PDE5 inhibitors (Cialis/tadalafil) for men who want both the desire bump and the vascular assist.
Heavy users who run PT-141 weekly start to notice mild mole darkening or freckle deepening over months (melanocortin pathway hits MC1R secondarily). Not a safety issue but a cosmetic signal that intake is meaningful. Take a break every 4-6 weeks if doing 3x/week to let pigmentation reset.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
](https://pubmed.ncbi.nlm.nih.gov/31135737/) - pivotal Phase 3 efficacy/safety in 1247 premenopausal women with HSDD
Read study ↗PubMedKingsberg et al, Bremelanotide for HSDD: Two Randomized Phase 3 Trials, Obstetrics & Gynecology 2019primary efficacy paper
Read study ↗PubMedMelanocortin receptor agonists and sexual function, IJIR 2008early male ED data, intranasal bremelanotide
Read study ↗PubMedPT-141 mechanism review, Pharmacol Rev 2018melanocortin pathway in central sexual response
Read study ↗PubMedBremelanotide BP and CV safety profile, J Sex Med 2019transient BP increases, CV monitoring guidance
Read study ↗Clinical guidelinesFDA Vyleesi approval announcement, June 2019official FDA approval for HSDD in premenopausal women
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Nausea: most-reported, especially first 1-3 doses. Community workaround is Dramamine or ginger 30 min before injection, smaller test dose (0.5 mg) first, and dosing on an empty stomach to avoid stomach-content compounding.
- Divergence: RCT pegs nausea at 40%, community reports closer to 50-60% for first-dose response but rapid tachyphylaxis (the side effect fades faster than the desired effect, so users tolerate it within a few sessions)
Flushing / "going red as a tomato": frequent, lasts 30-90 minutes, more pronounced on fair skin. Customer phrasing in PP's own dump: "I tried PT-141 and I went as red as a tomato and felt really sick"
Spontaneous erections / increased baseline libido for 24-48 hours post-dose: men report a tail effect well past the initial 6-8 hour central window
Yawning: melanocortin agonism produces excessive yawning during the onset window, ~30-90 min post-dose. Not dangerous but a known signature.
Penile/genital tingling within 30-60 minutes of injection (men): the most reliable "it's working" signal
Route: SubQ injection (research community standard; Vyleesi autoinjector is also SubQ)
Injection site: lower abdomen or outer thigh, rotate sites. Same routine as MT2/insulin pin.
Storage: refrigerated, stable ~30-45 days reconstituted. Unmixed vials are stable at room temp short-term but refrigerate for long storage.
Notes: Timing matters. Inject 30-90 minutes before intended activity, not at the moment. Eating a heavy meal before the dose doesn't block absorption but compounds nausea risk, so most users dose on an empty or light stomach. Do NOT dose more than once per 24 hours. Vyleesi's label caps at 8 doses per month to limit pigmentation and BP exposure; community treats this as a soft ceiling, not a hard one.